FEC→T is named as an intervention in 2 current clinical trials in our Germany, Sweden, Austria and Netherlands registers. None are recruiting at the moment. All registered phases are Phase 3. The sponsor with the most trials is Karolinska University Hospital (1). The most-studied condition is Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients
NCT00798070 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 3 | Active, closed | Karolinska University Hospital | Germany, Sweden, Austria |
|
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
NCT01996267 · ClinicalTrials.gov ↗ · Breast Cancer, HER2 Positive
|
Phase 3 | Active, closed | The Netherlands Cancer Institute | Netherlands |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Karolinska University Hospital | 1 |
| The Netherlands Cancer Institute | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Germany | 1 | 0 |
| Clinical trials in Sweden | 1 | 0 |
| Clinical trials in Austria | 1 | 0 |
| Clinical trials in Netherlands | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our Germany, Sweden, Austria and Netherlands registers name FEC→T as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Karolinska University Hospital (1) and The Netherlands Cancer Institute (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how FEC→T works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how FEC→T works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists FEC→T (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.